Ken Griffin’s Chemomab Therapeutics CMMB Stock Holding History

Ken Griffin’s Portfolio CMMB Stock Details CMMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Sell	64,182 -39,599	-38%	-$67.7K	﹤0.01%	12015
2025 Q4	$171K	Buy	+103,781	New	+$275K	﹤0.01%	11178
2024 Q3	–	Sell	-15,601	Closed	-$57.4K	–	14330
2024 Q2	$57.4K	Buy	+15,601	New	+$54K	﹤0.01%	11604
2024 Q1	–	Sell	-8,169	Closed	-$16.7K	–	14645
2023 Q4	$16.7K	Buy	+8,169	New	+$21.5K	﹤0.01%	12782
2022 Q4	–	Sell	-5,307	Closed	-$53K	–	14911
2022 Q3	$53K	Buy	+5,307	New	+$68.4K	﹤0.01%	11581
2021 Q1	–	Sell	-190	Closed	-$21K	–	13211
2020 Q4	$21K	Buy	+190	New	+$18.3K	﹤0.01%	10771

Other funds holding CMMB

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KPWS

Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

SmartHarvest Portfolios Poulsbo, Washington $309M AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

PIP

Philadelphia Investment Partners Voorhees, New Jersey $147M AUM

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ken Griffin's CMMB Position: Q1 2026 in Review

Ken Griffin reduced its Chemomab Therapeutics (CMMB) stake by 38% in Q1 2026, selling an estimated $67.7K and leaving 64,182 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #12015.

Ken Griffin first reported a position in CMMB in Q4 2020 and has held it in 6 quarters since. The position peaked at $171K in Q4 2025. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

Ken Griffin held 64,182 shares of Chemomab Therapeutics worth $101K as of Q1 2026.
Ken Griffin sold 39,599 Chemomab Therapeutics shares in Q1 2026, an estimated $67.7K.
Chemomab Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #12015 holding.
Ken Griffin first reported a position in Chemomab Therapeutics in Q4 2020 and has held it in 6 quarters since.
Ken Griffin's Chemomab Therapeutics position peaked at $171K in Q4 2025.
15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.